Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:3347 |
Name | osteosarcoma |
Definition | A bone sarcoma that is located_in bone that has_material_basis_in cells of mesenchymal origin. |
Source | DiseaseOntology.org |
Alt Ids | DOID:183 |
Path | disease disease of cellular proliferation cancer organ system cancer musculoskeletal system cancer connective tissue cancer bone cancer bone sarcoma osteosarcoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
Unknown unknown | BMS-754807 | osteosarcoma | not applicable | detail... |
Unknown unknown | Dasatinib | osteosarcoma | not applicable | detail... |
NOTCH1 I1680S | MRK-003 | osteosarcoma | sensitive | detail... |
NOTCH1 E1567K | MRK-003 | osteosarcoma | sensitive | detail... |
NOTCH1 A1552G | MRK-003 | osteosarcoma | sensitive | detail... |
NOTCH1 A1552V | MRK-003 | osteosarcoma | sensitive | detail... |
NOTCH1 A1570G | MRK-003 | osteosarcoma | sensitive | detail... |
NOTCH1 V1575A | MRK-003 | osteosarcoma | sensitive | detail... |
NOTCH1 V1599M | MRK-003 | osteosarcoma | sensitive | detail... |
NOTCH1 A1707T | MRK-003 | osteosarcoma | sensitive | detail... |
NOTCH1 R1683W | MRK-003 | osteosarcoma | sensitive | detail... |
NOTCH1 V1676I | MRK-003 | osteosarcoma | sensitive | detail... |
Unknown unknown | YW3-56 | osteosarcoma | not applicable | detail... |
Unknown unknown | VCN-01 | osteosarcoma | not applicable | detail... |
RB1 mutant | VCN-01 | osteosarcoma | sensitive | detail... |
Unknown unknown | AZD7762 + VE-821 | osteosarcoma | not applicable | detail... |
Unknown unknown | AZD7762 + Hydroxyurea + VE-821 | osteosarcoma | not applicable | detail... |
CBLC dec exp | Olaparib | osteosarcoma | predicted - sensitive | detail... |
SMO dec exp | SANT1 | osteosarcoma | predicted - sensitive | detail... |
Unknown unknown | WZ4003 | osteosarcoma | not applicable | detail... |
Unknown unknown | HTH-01-015 | osteosarcoma | not applicable | detail... |
Unknown unknown | V158411 | osteosarcoma | not applicable | detail... |
Unknown unknown | Pembrolizumab | osteosarcoma | not applicable | detail... |
Unknown unknown | Prexasertib | osteosarcoma | not applicable | detail... |
Unknown unknown | Gemcitabine + Sirolimus | osteosarcoma | not applicable | detail... |
Unknown unknown | Capmatinib | osteosarcoma | not applicable | detail... |
Unknown unknown | NKTR-214 | osteosarcoma | not applicable | detail... |
STAG2 negative | Cisplatin | osteosarcoma | predicted - resistant | detail... |
PDGFRA D846V | Sorafenib | osteosarcoma | predicted - sensitive | detail... |
Unknown unknown | DSP-0509 | osteosarcoma | not applicable | detail... |
Unknown unknown | SP-2509 | osteosarcoma | not applicable | detail... |
AKT1 amp | MK2206 | osteosarcoma | sensitive | detail... |
BRAF G469V | Trametinib | osteosarcoma | no benefit | detail... |
Unknown unknown | Saracatinib | osteosarcoma | no benefit | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00902044 | Phase I | Fludarabine Cyclophosphamide HER2 sensitized T-cells | Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma | Active, not recruiting | USA | 0 |
NCT01241162 | Phase I | Decitabine | Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma | Completed | USA | 0 |
NCT01331135 | Phase I | Sirolimus | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors | Completed | USA | 0 |
NCT01518413 | Phase I | Irinotecan + Sorafenib | Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors | Completed | USA | 0 |
NCT01759303 | Phase II | Pazopanib | Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung | Terminated | USA | 0 |
NCT01956669 | Phase II | Pazopanib | Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors | Completed | USA | CAN | 5 |
NCT02013336 | Phase I | Cyclophosphamide + MM-398 | Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors | Recruiting | USA | 0 |
NCT02048371 | Phase II | Regorafenib | A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas | Recruiting | USA | 0 |
NCT02100891 | Phase II | Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors | Active, not recruiting | USA | 0 | |
NCT02173093 | Phase Ib/II | Aldesleukin + GD2Bi-aATC + Sargramostim | Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma | Unknown status | USA | 0 |
NCT02304458 | Phase Ib/II | Ipilimumab + Nivolumab | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | Active, not recruiting | USA | CAN | 0 |
NCT02357810 | Phase II | Pazopanib + Topotecan | Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas | Active, not recruiting | USA | 0 |
NCT02432274 | Phase Ib/II | Etoposide Lenvatinib Cyclophosphamide | Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies | Active, not recruiting | USA | 5 |
NCT02446431 | Phase I | Cyclophosphamide Bevacizumab Temsirolimus Valproic acid | Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence | Recruiting | USA | 0 |
NCT02470091 | Phase II | Denosumab | Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma | Active, not recruiting | USA | CAN | 1 |
NCT02487979 | Phase II | Glembatumumab vedotin | Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma | Completed | USA | CAN | 1 |
NCT02644460 | Phase I | Abemaciclib | Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors | Recruiting | USA | 0 |
NCT02789228 | Phase I | MultiTAA-specific T cells | Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors (REST) | Recruiting | USA | 0 |
NCT02815995 | Phase II | Durvalumab + Tremelimumab | Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes | Active, not recruiting | USA | 0 |
NCT02879162 | Phase II | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours | Active, not recruiting | CAN | 0 |
NCT02982941 | Phase I | MGA271 | Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors | Completed | USA | 0 |
NCT03006848 | Phase II | Avelumab | A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma | Active, not recruiting | USA | 0 |
NCT03139331 | Phase I | Irinotecan + Pazopanib + Temozolomide | PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma | Completed | USA | 0 |
NCT03190174 | Phase Ib/II | Nab-Rapamycin + Nivolumab | Nivolumab (Opdivo) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma | Recruiting | USA | 0 |
NCT03282344 | Phase II | Nivolumab + NKTR-214 | A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma | Active, not recruiting | USA | 0 |
NCT03320330 | Phase Ib/II | Pepinemab | VX15/2503 in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors | Active, not recruiting | USA | 0 |
NCT03422679 | Phase Ib/II | CB-103 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | Recruiting | USA | 3 |
NCT03449108 | Phase II | Cyclophosphamide + Fludarabine + Interleukin-12 + LN-145 + Mesna | Iovance Alliance: LN-145 Across Multiple Tumor Types | Recruiting | USA | 0 |
NCT03458728 | Phase Ib/II | Copanlisib | Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients | Recruiting | USA | 0 |
NCT03628209 | Phase Ib/II | Azacitidine + Nivolumab | Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma | Recruiting | USA | 0 |
NCT03635632 | Phase I | C7R-GD2.CART cells Cyclophosphamide + Fludarabine | C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) | Recruiting | USA | 0 |
NCT03698994 | Phase II | Ulixertinib | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | Recruiting | USA | 1 |
NCT03718091 | Phase II | Berzosertib | M6620 (VX-970) in Selected Solid Tumors | Active, not recruiting | USA | 0 |
NCT03860207 | Phase Ib/II | Hu3F8-BsAb | Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers | Recruiting | USA | 0 |
NCT03900793 | Phase I | Losartan + Sunitinib | Losartan + Sunitinib in Treatment of Osteosarcoma | Recruiting | USA | 0 |
NCT03960177 | Phase I | Glucarpidase | Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma | Recruiting | USA | 0 |
NCT04040205 | Phase II | Abemaciclib | Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration | Recruiting | USA | 0 |
NCT04154189 | Phase II | Etoposide + Ifosfamide Etoposide + Ifosfamide + Lenvatinib | A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma | Recruiting | USA | 18 |
NCT04183062 | Phase II | BIO-11006 + Docetaxel + Gemcitabine | BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases | Recruiting | USA | 0 |
NCT04417062 | Phase II | AZD6738 + Olaparib | Olaparib With Ceralasertib in Recurrent Osteosarcoma | Recruiting | USA | 0 |
NCT04469530 | Phase II | Celecoxib + Cyclophosphamide + Etoposide + Sirolimus | Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors (AflacST1903) | Recruiting | USA | 0 |
NCT04616560 | Phase II | Trastuzumab deruxtecan | Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma | Recruiting | USA | 0 |
NCT04661852 | Phase I | Cabozantinib + Cyclophosphamide + Pegfilgrastim + Topotecan Cabozantinib + Cyclophosphamide + Filgrastim + Topotecan | Cabozantinib With Topotecan-Cyclophosphamide | Recruiting | USA | 0 |
NCT04668300 | Phase II | Durvalumab + Oleclumab | Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma (DOSa) | Recruiting | USA | 0 |